Jefferies Group Initiates Coverage on Odonate Therapeutics (ODT)

Research analysts at Jefferies Group assumed coverage on shares of Odonate Therapeutics (NASDAQ:ODT) in a note issued to investors on Tuesday. The brokerage set a “buy” rating and a $40.00 price target on the stock. Jefferies Group’s price target would indicate a potential upside of 65.77% from the stock’s previous close. Jefferies Group also issued estimates for Odonate Therapeutics’ Q4 2017 earnings at ($0.46) EPS, FY2017 earnings at ($1.83) EPS, Q1 2018 earnings at ($0.56) EPS, Q2 2018 earnings at ($0.69) EPS, Q3 2018 earnings at ($0.83) EPS, Q4 2018 earnings at ($0.96) EPS, FY2018 earnings at ($3.03) EPS and FY2019 earnings at ($3.21) EPS.

Shares of Odonate Therapeutics (NASDAQ ODT) traded down $0.60 during trading hours on Tuesday, hitting $24.13. 37,800 shares of the company’s stock were exchanged, compared to its average volume of 60,200. Odonate Therapeutics has a 52 week low of $22.31 and a 52 week high of $25.36.

In related news, Director Boxer Capital, Llc bought 416,666 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were purchased at an average cost of $24.00 per share, with a total value of $9,999,984.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin C. Tang bought 1,291,666 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was bought at an average cost of $24.00 per share, for a total transaction of $30,999,984.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 1,709,332 shares of company stock worth $41,023,268.

WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at

About Odonate Therapeutics

Odonate Therapeutics, LLC is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply